STOK Stock Risk & Deep Value Analysis
Stoke Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About STOK Stock
We analyzed Stoke Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran STOK through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
STOK Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is the failure or inconclusive outcome of the pivotal Phase 3 EMPEROR study for STK-001. A negative readout in mid-2027 would severely impact the stock price and the validation of Stoke's TANGO platform, given STK-001 is the lead asset.
Risk Matrix
Overall
Aggressive
Financial
Low
Market
Low
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Insider selling of ~$2.53M over the last 90 days, though minor for the company's size.
- ⚠
Lack of consistent revenue and current unprofitability, relying heavily on clinical success.
Upcoming Risk Events
- 📅
Negative or inconclusive Phase 3 clinical trial results for STK-001
- 📅
Unexpected safety signals emerging from ongoing trials
- 📅
Delay in regulatory approval process for STK-001
When to Reconsider
- 🚪
Exit if Phase 3 EMPEROR trial results are unequivocally negative or show insufficient efficacy.
- 🚪
Sell if cash runway is projected to be less than 12 months without clear financing plans.
- 🚪
Exit if significant competitor emerges with superior data for Dravet Syndrome.
Unlock STOK Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Stoke Therapeutics Inc (STOK) Do?
Market Cap
$2.06B
Sector
Healthcare
Industry
Biotechnology
Employees
128
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Visit Stoke Therapeutics Inc WebsiteInvestment Thesis
Stoke Therapeutics is a high-risk, high-reward investment poised for significant growth if its lead asset, STK-001, succeeds in pivotal Phase 3 trials for Dravet Syndrome. Its innovative TANGO platform addresses a high unmet medical need, offering potential market leadership in a niche but lucrative rare disease segment, backed by a strong cash position and clear clinical milestones.
Is STOK Stock Undervalued?
Unlock the full AI analysis for STOK
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
STOK Price Targets & Strategy
12-Month Target
$45.00
Bull Case
$60.00
Bear Case
$20.00
Valuation Basis
Based on analyst consensus high price target and discounted future revenue potential from STK-001's expected clinical milestones and platform validation.
Entry Strategy
Dollar-cost average between $30-$33, capitalizing on current price levels prior to Q1 earnings and Phase 3 enrollment completion.
Exit Strategy
Take 50% profit at $45, re-evaluate after mid-2027 Phase 3 data for STK-001; stop loss at $28.
Portfolio Allocation
5% for aggressive risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is STOK Financially Healthy?
Valuation
P/E Ratio
-218.32
Forward P/E
317.00
Price/Sales
10.63
Profitability
Operating Margin
-11.16%
Net Margin
-3.73%
Return on Equity
-2.05%
Revenue Growth
404.50%
EPS
$-0.13
Balance Sheet
Current Ratio
5.28
Quick Ratio
5.13
Debt/Equity
0.01
Cash & Equivalents
$390.00M
Cash Flow
Free Cash Flow
$43.60M
EBITDA
-$16.41M
Other
Beta (Volatility)
1.21
Does STOK Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily driven by intellectual property protecting the TANGO platform and STK-001. Successful clinical development and subsequent regulatory approval would validate the platform, potentially securing long-term market exclusivity for STK-001 and enabling broader application across other genetic diseases, thereby strengthening the moat.
Moat Erosion Risks
- •Clinical trial failure or unexpected adverse events for lead programs.
- •Emergence of superior or more cost-effective gene therapy/RNA technologies from competitors.
- •Patent challenges or expiration reducing intellectual property protection.
STOK Competitive Moat Analysis
Sign up to see competitive advantages
STOK Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral; specific data not provided, but generally optimistic for high-potential biotech.
Institutional Sentiment
Positive; Analyst consensus is Moderate Buy/Strong Buy with average price targets indicating 26-36% upside.
Insider Activity (Form 4)
Insiders sold 69,699 shares for approximately $2.53M over the last 90 days, representing a minor portion of insider holdings (9.5% ownership). No specific CEO/CFO activity flagged in the provided data.
Options Flow
Normal options activity; no specific unusual put/call ratio or large block trades flagged in the research.
Earnings Intelligence
Next Earnings
2026-05-07
Surprise Probability
Medium
Historical Earnings Pattern
Biotech earnings reports, especially for clinical-stage companies, often see significant stock volatility depending on clinical updates and cash burn rates rather than revenue/EPS figures.
Key Metrics to Watch
Competitive Position
Top Competitor
Sarepta Therapeutics (SRPT) - A leader in rare disease gene therapy with approved products, demonstrating successful commercialization.
Market Share Trend
Not applicable; Stoke is pre-commercial for its lead asset. Future market share will depend entirely on STK-001's approval and commercial success.
Valuation vs Peers
STOK's P/S ratio of 3.3x is in line with the sector median (3.0x-3.7x), and its P/B ratio of 1.5x-1.8x is below the sector median (2.6x), suggesting a reasonable valuation for a clinical-stage biotech.
Competitive Advantages
- •Proprietary TANGO platform for targeted gene augmentation.
- •STK-001's novel mechanism addressing the root cause of Dravet Syndrome.
- •Orphan drug designation for STK-001 providing market exclusivity.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive STOK Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Release (2026-05-07)
- •Completion of Phase 3 EMPEROR enrollment for STK-001 (Q2 2026)
Medium-Term (6-18 months)
- •Top-line data readout from Phase 3 EMPEROR study for STK-001 (Mid-2027)
- •Potential initiation of regulatory submissions (post-2027 based on data)
Long-Term (18+ months)
- •Expansion of TANGO platform to additional rare genetic diseases (beyond Dravet Syndrome)
- •Potential commercial launch of STK-001 in major markets
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for STOK?
- ✓
Positive efficacy and safety data from the Phase 3 EMPEROR study for STK-001.
- ✓
Expansion of the TANGO platform pipeline with new clinical candidates.
- ✓
Maintaining a strong cash position and effective cash burn management.
Bull Case Analysis
See what could go right with Premium
Competing with STOK
See how Stoke Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Stoke Therapeutics Inc STOK | $2.1B | 8.9 | -218.3 | $184.4M | -3.7% | 404.5% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Stoke Therapeutics Inc Makes Money
Stoke Therapeutics is a biotechnology company focused on developing RNA-based medicines to treat the underlying cause of severe genetic diseases. Their primary approach is through the proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform, which aims to increase protein expression to normalize function in conditions where too little protein is produced. Their lead product candidate, zorevunersen (STK-001), is in pivotal Phase 3 clinical trials for Dravet Syndrome, a severe form of epilepsy. Currently, the company generates revenue primarily from collaborations and grants, with significant future revenue expected to come from product sales if STK-001 receives regulatory approval.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Stoke Therapeutics Inc (STOK)?
As of May 4, 2026, Stoke Therapeutics Inc has a DVR Score of 8.9 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Stoke Therapeutics Inc?
Stoke Therapeutics Inc's market capitalization is approximately $2.1B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Stoke Therapeutics Inc use?
STOK is the ticker symbol for Stoke Therapeutics Inc. The company trades on the NMS.
What is the risk level for STOK stock?
Our analysis rates Stoke Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of STOK?
Stoke Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -218.3. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Stoke Therapeutics Inc's revenue growing?
Stoke Therapeutics Inc has reported revenue growth of 404.5%. The company is showing strong top-line momentum.
Is STOK stock profitable?
Stoke Therapeutics Inc has a profit margin of -3.7%. The company is currently unprofitable.
How often is the STOK DVR analysis updated?
Our AI-powered analysis of Stoke Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 4, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for STOK (Stoke Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.